South San Francisco's CytomX Files for $100 Million IPO
Published: Aug 31, 2015
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2015 /PRNewswire/ -- CytomX Therapeutics, Inc., a biopharmaceutical company developing Probody therapeutics for the treatment of cancer, today announced the filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. CytomX intends to list its common stock under the symbol "CTMX" on the NASDAQ Global Market.
BofA Merrill Lynch, Jefferies LLC and Cowen and Company LLC will act as joint book-running managers for the offering. Oppenheimer & Co. will serve as manager for the offering.
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attention: Prospectus Department, or by email at email@example.com; Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; or Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 631-274-2806 or by fax at 631-254-7140.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cytomx-files-registration-statement-for-proposed-initial-public-offering-300134857.html
SOURCE CytomX Therapeutics